Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 11/20 | 0.61 |
| ▸ | CCKAR | P32238 | 3/20 | 0.61 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.55 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.55 |
| ▸ | CTSC | P53634 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30051293 | 0.91 | CTSC (0.65) | CCKBRCCKARERAP2OPRD1CTSC | |
| SCHEMBL29717264 | 0.87 | CCKBR (0.61) | CCKBRCCKARERAP2OPRD1CTSC | |
| SCHEMBL29366904 | 0.87 | ERAP2 (0.60) | ERAP2OPRD1MEN1KMT2A | |
| SCHEMBL29497501 | 0.85 | CCKBR (0.75) | CCKBRCCKAROPRD1 | |
| SCHEMBL9194598 | 0.85 | CCKBR (0.54) | CCKBRCCKARERAP2OPRD1 | |
| SCHEMBL9194589 | 0.85 | CCKBR (0.54) | CCKBRCCKARERAP2OPRD1 | |
| SCHEMBL29886823 | 0.85 | ERAP2 (0.58) | ERAP2OPRD1MEN1KMT2A | |
| SCHEMBL30052005 | 0.85 | CTSC (0.69) | ERAP2CTSCMEN1KMT2A | |
| SCHEMBL29516510 | 0.85 | CCKBR (0.75) | CCKBRCCKAROPRD1 | |
| SCHEMBL17534378 | 0.84 | ERAP2 (0.60) | CCKBRCCKARERAP2CTSCMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | Biocrucible Limited (GB) | 2026-05-05 | — | — | US | disclosed |
| US-20220112547-A1 | BIOCHEMICAL REACTION METHODS AND REAGENTS COMPRISING INTRINSICALLY DISORDERED REGIONS | Biocrucible Limited (GB) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | POLM, POLR1A, POLR1E | CCKBR 3793/4885CCKAR 4339/4885ERAP2 2458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.